INDIANAPOLIS, Feb. 9, 2024
/PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced
that after more than 28 years, Philip
Johnson, group vice president and treasurer, will retire
from the company at the end of February to pursue a new
professional opportunity.
"Phil has had a meaningful impact on Lilly over the last 28
years," said Anat Ashkenazi, executive vice president and chief
financial officer at Lilly. "Through his deep financial knowledge
and understanding of the business, industry and stakeholders, Phil
has played a key leadership role in the company and is well
recognized for his commitment to Lilly's purpose and the patients
we serve. Additionally, he is known for his passion for talent
development, having invested significant time mentoring and
coaching colleagues across the globe."
Throughout his tenure, Johnson supported a variety of
operations, including Lilly affiliates in Japan and Spain, global manufacturing and quality
organizations, and business development activities. He led Lilly's
investor relations group for 11 years and was consistently named
Top Investor Relations Officer by Institutional Investor. He has
served as Lilly's treasurer since 2018 and has led the company's
efforts within the financial community to drive positive social and
economic change for underrepresented groups.
Johnson's successor will be named at a future date.
About Lilly
Lilly is a medicine company turning science into healing to make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help more than 51 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. C-LLY
Lilly Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995), including related to leadership changes and Lilly's
strategy, and reflects Lilly's current beliefs and expectations.
There can be no assurance that the leadership changes will achieve
Lilly's objectives or that Lilly will execute its strategy as
planned. For further discussion of risks and uncertainties relevant
to Lilly's business, please see Lilly's most recent Forms 10-K and
10-Q filed with the U.S. Securities and Exchange Commission. Lilly
undertakes no duty to update forward-looking statements.
Refer to: Carrie
Munk, munk_carrie@lilly.com, 317-416-2393
View original content to download
multimedia:https://www.prnewswire.com/news-releases/philip-johnson-to-retire-as-lilly-treasurer-302058585.html
SOURCE Eli Lilly and Company